Skip to main content
Category

COMPANIES

SOM Biotech identifies eravacycline as an effective treatment against SARS-CoV-2

The biopharmaceutical company SOM Biotech,based in the Barcelona Science Park, announces the preclinical validation studies of eravacycline as an effective treatment against SARS-CoV-2. The conclusions of the studies will be presented at the virtual event IDWeek 2020. that will be held from October 21 to 25. Eravacycline is one of the three drugs that the company has identified and validated in collaboration with Ewha Womans University for the treatment of the new coronavirus, and SOM already plans to carry out a Phase 2 clinical trial.

 

 

Read More

Scott Boyer joins Chemotargets as new CEO

Chemotargets, a global leader in predictive analytics solutions for the pharma and biotech sector, has appointed Dr. Scott Boyer as new CEO. He takes over from Dr. Jordi Mestres, who becomes Chief Scientific Officer and will maintain his position as President of the Board. With the new incorporation, the company, based in the Barcelona Science Park, consolidates its transition from a software business to an AI-driven biotech company.

 

Read More

Oncoheroes receives from FDA the Rare Pediatric Disease Designation (RPDD) to volasertib for rhabdomyosarcoma

Oncoheroes Bioscience –a Boston based biotech with the European subsidiary at the Barcelona Science Park– focused on advancing new therapies for childhood cancer, is pleased to announce that the United States Food and Drug Administration (FDA) has granted the designation of rare pediatric disease to volasertib, an investigational treatment for rhabdomyosarcoma.

 

Read More

SOM Biotech appoints Alain Duguet PhD as Head of Chemical Manufacturing and Control

The biotech company SOM Biotech, based in the Barcelona Science Park and specialized in drug development and discovery, has named Alain Duguet as the new head of Chemical Manufacturing and Control. Duguet is an accredited consultant and expert in the definition, management, evaluation and optimization of the production processes of medicines for the pharmaceutical industry. He has worked in the pharmaceutical industry for over three decades for large multinationals, including Sanofi, where he led this area for over 15 years.

 

Read More

Kumux launches a 2.0 software which creates differential light to improve human health and plant growth

A spin-off by the University of Barcelona Enlighting Technologies, based in the Barcelona Science Park, has created Kumux to launch a 2.0 simulation spectrum software which, through patented algorithms, creates a differential light with beneficial effects for health for both people and plant growth. It is an smart lighting solution –autonomous and based on LED technology–, compatible with different systems and designed so that it can be integrated into any luminaire or control platform.

 

Read More

Judit Cubedo, CEO of GlyCardial, finalist for the EU Prize for Women Innovators 2020

Judit Cubedo, co-founder and CEO of GlyCardial Diagnostics, is one of the twenty-one women selected as finalists for the EU Prize for Women Innovators 2020, an award given annually to the most talented and inspiring entrepreneurs in Europe. The company led by Judit, which is based in the Barcelona Science Park, is conducting a clinical trial to validate the performance of Apo J-Glyc as a novel biomarker for the early detection of Myocardial Ischaemia. The award winners will be announced at the European Research and Innovation Days taking place on 22-24 September 2020.

 

Read More

Launch of the company Gate2Brain, based on novel technology developed at IRB Barcelona to transport drugs into the brain

The Institute for Research in Biomedicine (IRB Barcelona), the University of Barcelona (UB) and the Sant Joan de Déu Research Institute (IRSJD)- Hospital Sant Joan de Déu (SJD) have set up Gate2Brain, a company based on a novel technology to transport drugs into the brain. The biotech, based in the Barcelona Science Park, is the second joint spin-off between IRB Barcelona and the UB to be funded by the Mind the Gap Programme run by the Botín Foundation.

 

Read More